Novartis enters into agreement for exclusive US and Canadian rights to Fanapt(TM)
- Details
- Category: Novartis
![Novartis Pharma AG Novartis Pharma AG](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
GSK's Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline (GSK) GlaxoSmithKline (GSK)](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
Onyx Pharmaceuticals to Acquire Proteolix, Inc.
- Details
- Category: Business
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has signed a definitive agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry
- Details
- Category: Pfizer
![Pfizer Inc. Pfizer Inc.](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
Access to HIV medication
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](http://www.worldpharmanews.com/images/stories/logo/boehringeringelheim.gif)
GSK expands presence in China through strategic cooperation
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline (GSK) GlaxoSmithKline (GSK)](http://www.worldpharmanews.com/images/stories/logo/gsk.gif)
Sandoz launches somatropin, the first-ever Japanese biosimilar
- Details
- Category: Novartis
![Novartis Novartis](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
More Pharma News ...
- Takeda to Establish Four Sales and Marketing Subsidiaries
- Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
- Merck Submits Application for Cladribine Tablets
- The Lilly TB Drug Discovery Initiative Announces New Collaborator
- Abbott to Acquire Solvay Pharmaceuticals Business
- Novartis bronchodilator QAB149 recommended for approval in European Union
- Results from Abbott's PROSPECT Study Provide New Insight